EUVIMEDEUVIMED entdecken
Crossref

Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG

Laura Segalés, Nuria Juanpere, Marta Lorenzo, Beatriz Casado, Sílvia de Muga, Marta Salido, Alejo Rodriguez-Vida, Lluís Fumadó, Lluís Cechinni, Joaquim Bellmunt, Silvia Hernández-Llodrà

Molecular Biology Reports · 2026

DOI: 10.1007/s11033-025-11258-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, 2026. Verfasst von Laura Segalés und 10 weiteren Autor:innen. Beteiligte Einrichtung: Departament of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proto-Oncogene Protein c-ets-2, Tumor Suppressor Protein p53, Transcriptional Regulator ERG. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Spanish Ministry of Health, “Beca Leonardo de la Peña 2022” through the Foundation for Research in Urology of the Spanish Association of Urology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: ETS2 expression in prostate cancer (PCa) shows variability, with overexpression and loss reported. ETS2 can be dysregulated through proteasomal degradation, but p53 missense mutants may stabilize ETS2 by preventing this process. TP53 mutations are more frequent in metastatic PCa, and their identification in primary tumors could serve as an early marker for patient stratification. In addition, TMPRSS2-ERG fusion often arises from an intrachromosomal deletion including ETS2 locus. METHODS AND RESULTS: ETS2, p53 and ERG protein expression were assessed by immunohistochemistry in a surgically treated PCa patients' cohort (N = 199). ETS2 and TMPRRS2-ERG mRNA were evaluated by qPCR in an independent series (N = 80). Relationship between molecular markers, and with clinicopathological characteristics was analyzed. High ETS2 protein expression was observed in 34.7% of tumors. Aberrant p53 immunostaining was detected in 5.5% of cases, being associated with high ETS2 expression (p = 0.050). p53 positivity was related to GG5 (p = 0.007) and unifocality (p = 0.011). Shorter time to PSA recurrence was observed in p53-positive patients (p = 0.002). Cases with high ETS2 expression but negative p53 staining had the longest time to recurrence, whereas p53-positive cases, regardless of ETS2, had the shortest (p = 0.002). ERG protein expression -surrogate marker of TMPRSS2-ERG- was strongly associated with high ETS2 (p < 0.001). At mRNA level, low ETS2 expression correlated with TMPRSS2-ERG fusion (p = 0.018), and showed a trend toward association with intrachromosomal deletion (p = 0.113) and high-stage (p = 0.054). CONCLUSIONS: In conclusion, p53 staining was consistently associated with aggressive PCa and may serve as a reliable prognostic marker. High ETS2 expression correlates with delayed PSA recurrence in p53-negative tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProto-Oncogene Protein c-ets-2Tumor Suppressor Protein p53Transcriptional Regulator ERGHumansMaleAgedMiddle AgedGene Expression Regulation, NeoplasticBiomarkers, TumorOncogene Proteins, FusionImmunohistochemistry

Stichwörter der Autor:innen

ERGETS2Fusion mechanismsImmunostainingP53TMPRSS2-ERG

Substanzen

Proto-Oncogene Protein c-ets-2Tumor Suppressor Protein p53Transcriptional Regulator ERGETS2 protein, humanERG protein, humanTP53 protein, humanBiomarkers, TumorOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Departament of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
  • Hospital del Mar Research Institute, Barcelona, Spain.
  • Department of Pathology, Hospital del Mar, Barcelona, Spain.
  • Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
  • Department of Urology, Hospital del Mar, Barcelona, Spain.
  • Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Förderung

  • Spanish Ministry of Health
  • “Beca Leonardo de la Peña 2022” through the Foundation for Research in Urology of the Spanish Association of Urology

Zitieren

APA

Segalés, L., Juanpere, N., Lorenzo, M., Casado, B., de Muga, S., Salido, M., Rodriguez-Vida, A., Fumadó, L., Cechinni, L., Bellmunt, J., & Hernández-Llodrà, S. (2026). Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-11258-9

Vancouver

Segalés L, Juanpere N, Lorenzo M, Casado B, de Muga S, Salido M, et al. Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG. Molecular Biology Reports. 2026. doi:10.1007/s11033-025-11258-9

BibTeX
@article{Segals2026,
  author = {Segalés, Laura and Juanpere, Nuria and Lorenzo, Marta and Casado, Beatriz and de Muga, Sílvia and Salido, Marta and Rodriguez-Vida, Alejo and Fumadó, Lluís and Cechinni, Lluís and Bellmunt, Joaquim and Hernández-Llodrà, Silvia},
  title = {Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG},
  journal = {Molecular Biology Reports},
  year = {2026},
  doi = {10.1007/s11033-025-11258-9}
}
Kostenlos starten →